Mitigating prolonged QT interval in cancer nanodrug development for accelerated clinical translation

BACKGROUND: Cardiac toxicity is the foremost reason for drug discontinuation from development to clinical evaluation and post market surveillance [Fung 35:293-317, 2001; Piccini 158:317-326 2009]. The Food and Drug Administration (FDA) has rejected many potential pharmaceutical agents due to QT prol...

Descripción completa

Detalles Bibliográficos
Autores principales: Ranjan, Amalendu P, Mukerjee, Anindita, Helson, Lawrence, Vishwanatha, Jamboor K
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3878673/
https://www.ncbi.nlm.nih.gov/pubmed/24330336
http://dx.doi.org/10.1186/1477-3155-11-40

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3878673/
https://www.ncbi.nlm.nih.gov/pubmed/24330336
http://dx.doi.org/10.1186/1477-3155-11-40

Ejemplares similares